Company intelligence / Profile preview
Kedrion Biopharma
Castelvecchio Pascoli, Tuscany, Italykedrion.com ↗
- Ownership
- Private
- Employees
- ~5200
- Development stage
- Other
01
Overview
Kedrion is a global leader in the collection and fractionation of human plasma to produce 38 vital medicines distributed worldwide. The company has FDA-approved products for rare diseases such as congenital plasminogen deficiency, with ongoing R&D focused on orphan drugs for ultra‐rare conditions. In 2024, it reported +10% growth and continues to expand its product portfolio and manufacturing capabilities.
- Therapeutic areas
- Women's HealthHematologyImmunologyNeurology
- Modalities
- Plasma-derived therapies/products
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
Beyond the preview
Go deeper on Kedrion Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kedrion Biopharma.